Forest Laboratories Inc

More

• Analyst downgrades Ironwood Pharma on expenses Monday, 6 May 2013 | 1:46 PM ET

  NEW YORK-- A Cowen& Co. analyst downgraded shares of Ironwood Pharmaceuticals Inc. Monday, citing the company's growing expenses and disappointing early sales of its bowel drug Linzess. THE OPINION: Analyst Edward Nash said he doesn't expect Ironwood to be profitable until 2017 and he doesn't expect the stock to trade higher for now.

• Almirall, Forest to seek approval for inhaler drug in US, Europe Thursday, 2 May 2013 | 3:47 AM ET

  MADRID, May 2- Spain's Almirall and Forest Laboratories said on Thursday that results of a second phase III clinical trial for a new inhaler were positive and they will seek regulatory approval to sell the drug by the end of the year.

• Almirall, Forest to seek approval for inhaler drug in US, Europe Thursday, 2 May 2013 | 3:47 AM ET

  MADRID, May 2- Spain's Almirall and Forest Laboratories said on Thursday that results of a second phase III clinical trial for a new inhaler were positive and they will seek regulatory approval to sell the drug by the end of the year.

• BRIEF-Forest Laboratories and Almirall report positive results for the second late-stage study Wednesday, 1 May 2013 | 2:22 PM ET

  May 1- Forest Laboratories Inc:. *Forest Laboratories and almirall announce positive results for the second. *Regulatory filings with the United States food& drug and European.

• Early Movers: DD, TRV, UTX & More Tuesday, 23 Apr 2013 | 8:13 AM ET

  

  Some of the names on the move ahead of the open.

• A Make-or-Break Week Ahead for the Stock Market Saturday, 20 Apr 2013 | 12:30 AM ET

  

  It's make-or-break time for the first-quarter earnings season, and it comes just as the stock market is showing signs of strain.

• Early Movers: KO, GS, JNJ & More Tuesday, 16 Apr 2013 | 8:11 AM ET

  

  Some of the names on the move ahead of the open.

• Almirall, Forest report positive results in inhaler trial Tuesday, 16 Apr 2013 | 2:58 AM ET

  MADRID, April 16- Spain's Almirall and Forest Laboratories said results of a first phase III clinical trial for Almirall's Genuair inhaler were positive and they would seek regulatory approval to sell the drug if further results proved positive.

• UPDATE 1-Optimer shares rise after report names Glaxo, Cubist as potential buyers Tuesday, 2 Apr 2013 | 2:29 PM ET

  *Optimer could get $15- $16/ shr- analyst. April 2- Shares of Optimer Pharmaceuticals Inc rose as much as 24 percent after a Bloomberg report said GlaxoSmithKline Plc and Cubist Pharmaceuticals Inc were among those interested in buying the antibiotic maker. The report also named AstraZeneca PLC and Japan's Astellas Pharma Inc as potential buyers.

• ANALYSIS-Antibiotics crisis prompts rethink on risks, rewards Monday, 18 Mar 2013 | 12:06 AM ET

  *Big Pharma retreat leaves antibiotic pipeline bare. *Low prices and limited usage key deterrents for industry. LONDON, March 18- Thirty years ago, when the world faced the terrifying prospect of an untreatable disease known as AIDS, big drugmakers scented an opportunity and raced to develop new medicines.

• US STOCKS-Wall St eyes lower open on debt limit, profit worries Tuesday, 15 Jan 2013 | 9:07 AM ET

  Wall Street was set to open lower on Tuesday as investors fretted over the debate brewing in Washington over raising the U.S. borrowing limit as well as what is expected to be a lackluster earnings season. The United States could default on its debt if Congress does not increase the borrowing limit.

• UPDATE 1-Forest posts loss as antidepressant sales plummet Tuesday, 15 Jan 2013 | 9:05 AM ET

  *Forest Labs posts much wider-than-expected loss.

• Early Movers: LEN, FRX, LULU & More Tuesday, 15 Jan 2013 | 7:51 AM ET

  

  Some of the names on the move ahead of the open.

• Forest posts 3rd-qtr loss as antidepressant sales plummet Tuesday, 15 Jan 2013 | 7:22 AM ET

  Jan 15- Forest Laboratories Inc on Tuesday posted a fiscal third-quarter loss as sales of its antidepressant Lexapro continued to be buffeted by generic competition. The company posted a net loss in the quarter that ended Dec. 31, of $153.6 million, or 58 cents a share, compared with a profit of $278.4 million, or $1.04 a year ago.

• Stocks Looking Beyond Debt Ceiling, for Now Monday, 14 Jan 2013 | 8:58 PM ET

  

  Stocks are so far looking past the brewing congressional debt ceiling drama but that could change quickly if it becomes very contentious.